Clinical Trial Update: A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age [Phase 1]

View source ↗

Summary

Phase I randomized, single-blind, controlled study to evaluate safety and immunogenicity of a glycoconjugate Group B Streptococcus vaccine in healthy women aged…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Group Streptococcus Disease

Drugs mentioned

• Glycoconjugate antigen vaccine of Group B Streptococcus (Glycoconjugate antigen vaccine targeting Group B Streptococcus)

Snippet

Sponsor: Novartis Vaccines | Conditions: Invasive Group B Streptococcus (GBS) Disease | Phase 1 | Status: COMPLETED